Ariane Medical Systems — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Ariane Medical Systems, founded in 2009, is a private medical device company focused on advancing contact X-ray brachytherapy (CXB) for accessible tumors. Its core innovation is the Papillon+ system, featuring patented Micronode™ technology, which delivers high-dose radiation directly to tumors or surgical cavities in minutes. The company has achieved a significant milestone with a positive NICE recommendation for its rectal cancer treatment, positioning it for growth in organ-preserving oncology therapies. Ariane targets the clinical and economic benefits of shorter, more targeted radiotherapy procedures.

OncologyRectal CancerSkin CancerBreast Cancer

Technology Platform

Patented Micronode™ low-energy X-ray generator enabling high-dose-rate (up to 20 Gy/min) contact brachytherapy (CXB) and intraoperative radiotherapy (IORT). The wireless, portable Papillon+ system delivers targeted radiation directly to tumors or surgical cavities for rectal, skin, and breast cancer applications.

Opportunities

The NICE recommendation for rectal cancer provides a major catalyst for adoption within the UK NHS, driven by compelling organ preservation and health economic arguments.

Globally, there is significant unmet need for efficient, targeted radiotherapy solutions that reduce surgery, hospital stays, and costs, aligning with healthcare trends toward value-based care.

The portable, multi-modal design of the Papillon+ system allows it to address several cancer indications with one platform, maximizing market reach.

Risk Factors

Market adoption faces hurdles from entrenched clinical practices and requires significant training and change management.

The company faces competition from other IORT devices and advanced external beam radiotherapy techniques.

International expansion is dependent on navigating complex and varied regulatory and reimbursement landscapes outside the UK.

Competitive Landscape

Ariane competes in the targeted radiotherapy space, primarily against other intraoperative radiotherapy systems like the Zeiss INTRABEAM (low-energy X-rays) and dedicated electron-based IORT devices. For rectal cancer, it competes with transanal surgical techniques (TEM/TAMIS) and watch-and-wait protocols supported by chemoradiation. For skin cancer, it competes with surgical excision, cryotherapy, and other superficial radiotherapy devices. Its key differentiator is the portability and multi-modal application of its single platform.

More companies in Oncology (General) →More companies in United Kingdom →